Published in Eur J Clin Pharmacol on January 04, 2016
The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics (2004) 31.85
New equations to estimate GFR in children with CKD. J Am Soc Nephrol (2009) 11.48
Underdiagnosis of hypertension in children and adolescents. JAMA (2007) 5.41
Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol (2008) 5.34
Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr (2007) 4.63
High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation (2007) 4.36
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13
Trends of elevated blood pressure among children and adolescents: data from the National Health and Nutrition Examination Survey1988-2006. Am J Hypertens (2008) 2.10
Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol (2008) 1.88
Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet (2006) 1.78
Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension (2008) 1.70
Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther (2003) 1.67
High blood pressure in children and adolescents. Am Fam Physician (2012) 1.67
A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension (2010) 1.48
A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol (2000) 1.37
Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child (2013) 1.25
Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet (2008) 1.23
Assessment and management of hypertension in children and adolescents. Nat Rev Cardiol (2010) 1.20
Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin Pharmacol Ther (2007) 1.18
A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens (2005) 1.13
Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother (2001) 1.02
The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol (2001) 1.00
Azilsartan medoxomil: a new Angiotensin receptor blocker. Clin Ther (2011) 0.94
Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig (2012) 0.92
Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens (Greenwich) (2011) 0.85
Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens (2010) 0.84
Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment. Clin Pharmacokinet (2013) 0.83
Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens (Greenwich) (2012) 0.82
Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) (2008) 0.82
Rational use of antihypertensive medications in children. Pediatr Nephrol (2013) 0.82
The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects. Clin Pharmacol Ther (2011) 0.81
Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. Paediatr Drugs (2012) 0.81
Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. J Clin Pharmacol (2009) 0.81
Pediatric hypertension: often missed and mismanaged. J Fam Pract (2014) 0.79
Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. J Hypertens (2013) 0.77
A randomized, open-label, dose-response study of losartan in hypertensive children. Clin J Am Soc Nephrol (2014) 0.77
Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension. J Clin Pharmacol (2016) 0.77
Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens (Greenwich) (2011) 0.85
A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor. Neuroimage (2016) 0.76
Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment. J Clin Pharmacol (2017) 0.75